Official Title: A M ulticenter, Randomized, Double-blind, P lacebo -controlled c linical s tudy 
to assess the efficacy and safety of T ildrakizumab  in the treatment of moderate to severe 
plaque psoriasis of the scalp 
 Document: Clinical Study Protocol  NCT number: [STUDY_ID_REMOVED] 
 Date: 17- Mar-2020
 
CONFIDENTIAL  Protocol TILD -18-20- 
  
 1  
TITLE PAGE  
Protocol Title :  A M ulticenter, Randomized, Double -Blind, P lacebo -Controlled 
Clinical Study  to Assess the Efficacy and Safety of Tildrakizum ab in 
the Treatment of Moderate to Sever e Plaque Psoriasis of the Scalp  
Protocol Number:   TILD-18-20 
   
   
Product :    Tildrakizumab  
Short Title:  Efficacy and Safety Profile of Tildraki zumab in Subjects with 
Moderate to Severe Plaque Psoriasis of the Scalp . 
Study Phase:    3b 
Sponsor Name :   Sun Pharma Global FZE  
Legal Registered Address:  Office # 43, Block Y,  
SAIF Zone  
Sharjah, 122304 
United Arab Emirates  
Regulatory Agency Identifying Number: IND number 101,389 
   
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 3 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 4 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 5 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 6 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 7 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 9  
TABLE OF CONTENTS  
SUMMARY OF CHANGES  .........................................................................................................3  
LIST OF APPENDICES  .............................................................................................................11  
LIST OF TABLES  .......................................................................................................................12  
LIST OF FIGURES  .....................................................................................................................12  
1.0 PROTOCOL SUMMARY ..............................................................................................13  
1.1 Synopsis .................................................................................................................13  
  
  
2.0 INTRODUCTION............................................................................................................25  
2.1 Background ............................................................................................................25  
2.2 Study Rationale  ......................................................................................................25  
2.3 Benefit/Risk Assessment  .......................................................................................26  
3.0 OBJECTIVES AND ENDPOINTS  ................................................................................27  
4.0 STUDY DESIGN ..............................................................................................................30  
4.1 Overall Design  .......................................................................................................30  
4.2 Scientific  Rationale for Study Design ....................................................................31  
4.3 Justification for Dose .............................................................................................31  
4.4 End of Study Definition .........................................................................................32  
5.0 STUDY POPULATION ..................................................................................................33  
5.1 Inclusion Criteria  ...................................................................................................33  
5.2 Exclusion Criteria  ..................................................................................................34  
5.3 Lifest yle Considerations ........................................................................................35  
5.4 Screen Failures  .......................................................................................................36  
6.0 STUDY TREATMENT  ...................................................................................................37  
  
6.2 Preparation/Handling/Storage/Accountability  .......................................................38  
6.3 Measures to Minimize Bias: Randomization and Blinding  ...................................38  
6.4 Study Treatment Compliance  ................................................................................39  
6.5 Concomitant Therapy.............................................................................................39  
6.5.1  Rescue Medicine  ...................................................................................40  
  
6.6 Dose Modification .................................................................................................40  
6.7 Treatment after the End of the Study .....................................................................40  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 10 7.0 DISCONTINUATION OF STUDY TREATMENT AND S UBJECT 
DISCONTINUATION/WITHDRAWAL  ......................................................................41  
7.1 Discontinuation of Study Treatment ......................................................................41  
7.1.1  Temporary Discontinuation ..................................................................41  
7.2 Subject Discontinuation/Withdrawal from the Study  ............................................42  
7.3 Lost to Follow-up ...................................................................................................42  
8.0 STUDY ASSESSMENTS AND PROCEDURES  ..........................................................44  
8.1 Efficacy Assessments .............................................................................................44  
8.1.1  Assessments for Scalp:  ..........................................................................45  
8.1.2  Assessments for Whole Body: ..............................................................45  
8.1.3  Dermatology Life Quality Index  ...........................................................46  
8.2 Safety Assessments  ................................................................................................46  
8.2.1  Phys ical Examinations  ..........................................................................47  
8.2.2  Vital Signs  .............................................................................................47  
8.2.3  Assessment of Suicidal Ideation and Behavior .....................................47  
8.2.4  Electrocardiograms  ...............................................................................48  
8.2.5  Tuberculosis Testing .............................................................................48  
8.2.6  Chest X -ray ...........................................................................................48  
8.2.7  Clinical Safety Laboratory Assessments  ...............................................48  
8.3 Adverse Events  ......................................................................................................49  
8.3.1  Time Period and Frequency for Collecting AE and SAE 
Information  ............................................................................................49  
8.3.2  Method of Detecting AEs and SAEs .....................................................50  
8.3.3  Follow-up of AEs and SAEs .................................................................50  
8.3.4  Regulatory Reporting Requirements for SAEs .....................................50  
8.3.5  Pregnancy  ..............................................................................................51  
8.3.6  Adverse Events of Special Interest  .......................................................52  
8.3.7  Events of Clinical Interest  .....................................................................52  
8.4 Treatment of Overdose  ..........................................................................................52  
8.5 Pharmacokinetics  ...................................................................................................53  
8.6 Pharmacodynamics  ................................................................................................53  
8.7 Genetics ..................................................................................................................53  
8.8 Biomarkers  .............................................................................................................53  
8.9 Health Economics or Medical Resource Utilization and Health Economics  ........53  
9.0 STATISTICAL CONSIDERATIONS  ...........................................................................54  
9.1 Statistical Hypotheses  ............................................................................................54  
9.2 Sample Size Determination ....................................................................................54  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 11 9.3 Populations for Analyses .......................................................................................55  
9.4 Statistical Analyses  ................................................................................................56  
9.4.1  Efficacy Analyses ..................................................................................57  
9.4.2  Safety Analyses  .....................................................................................59  
9.4.3  Other Analyses  ......................................................................................61  
  
9.5 Interim Analyses  ....................................................................................................61  
9.6 Monitori ng Committee ...........................................................................................61  
  
  
 
LIST OF APPENDICES  
 
Appendix 2:  ................. Regulatory, Ethical and study oversight considerations ............................66  
 
Appendix 4:  ................. Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting .......................................................77  
Appendix 5:  ................. Anaphylaxis  ...............................................................................................83  
Appendix 6:  ................. Excluded Medications/Therapy  .................................................................84  
Appendix 7:  ................. Contraceptive guidance and collection of pregnancy ................................85  
 
 
 
 
 
 
 
  
 
 
 
Appendix 19:  ............... Columbia- Suicide Severity Rating Scale  .................................................100  
 
 
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 12  
 
LIST  OF TABLES  
Table 1  ......................... Study Objectives and Endpoints  ................................................................27  
Table 2  ......................... Study Treatment Details  ............................................................................37  
Table 3  ......................... Analysis Sets  ..............................................................................................56  
Table 4  ......................... Efficacy Analyses  ......................................................................................57  
Table 5  ......................... Study Administrative Structure ..................................................................68  
Table 6  ......................... Protocol- required Safety Laboratory Assessments  ....................................74  
Table 7  ......................... Excluded Medications ................................................................................84  
 
LIST OF FIGURES  
Figure  1: ....................... Study Schema .............................................................................................21  
 
    
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 15 Objectives Endpoints  
• To assess the efficacy of tildrakizumab in 
subjects with moderate to severe plaque 
psoriasis of the scalp, as measured by the 
proportion of subjects who achieve at least 90% improvement from Baseline in the 
Psoriasis Scalp Severity Index (PSSI ) 
response at Week  16 compared with placebo. 
• To assess the efficacy of tildrakizumab in subjects with moderate to severe scalp 
psoriasis, as measured by the proportion of 
subjects who achieve IGA (Scalp only) of “clear” and “almost clear” with at least 2-point reduction from Baseline at Week 16. 
• To assess the efficacy of tildrakizumab in subjects with moderate to severe scalp 
psoriasis, as measured by the proportion of 
subjects who achieve Investigato r Global 
Assessment (IGA) mod 2011 (scalp) score of “clear” and “almost clear” with at least 2-point reduction from Baseline at Week 12. 
• To assess the efficacy of tildrakizumab in subjects with moderate to severe plaque 
psoriasis of the scalp, as measured by the 
proportion of subjects who achieve at least 90% improvement from Baseline in the Psoriasis Scalp Severity Index (PSSI) 
response at Week  12 compared with placebo. 
To assess the efficacy of tildrakizum ab in the 
treatment of moderate to severe plaque 
psoriasis of the scalp compared with  placebo 
as measured by  scalp surface area 
involvement at Week  16. • The proportion of subjects with at 
least 90% improvement from 
Baseline in the PSSI at Week  16. 
(Key secondary endpoint). 
• The proportion of subjects with IGA 
(scalp only) score of “clear” and “almost clear” with at least 2 -point 
reduction from Baseline at Week  16. 
(Key secondary endpoint). 
• The proportion of subjects with IGA 
mod 2011 (scalp) score of “clear” and “almost clear” with at least 2 -point 
reduction from Baseline at Week  12 
(key secondary endpoint) 
• The proportion of subjects with at least 90% improvement from 
Baseline in the PSSI at Week  12. 
(Key secondary endpoint). 
• Mean percentage change in PSSI 
score from Baseline to Week  16. 
• The proportion of subjects achieving PSSI  75 at Week  16. 
• The proportion of subjects achieving PSSI  100 at Week  16. 
• Mean percentage change in scalp surface area involvement from Baseline to Week  16. 
• To assess the effect of Tildrakizumab on IGA 
mod 2011 (scalp) and PSSI at other measured 
time points through week 52. 
• To assess the effect of tildrakizumab on, IGA (scalp only), Scalp Itch NRS, PASI, PGA -S 
(whole body), IGA mod 2011 (whole body ) at 
week 12 and other measured time points 
through Week 52.  • Change from baseline in IGA mod 2011 
(scalp)  and PSSI at other measured time 
points through Week 52. 
• Change from Baseline in IGA (scalp only), Scalp Itch NRS, PASI, PGA -S (whole body), 
and IGA mod 2011 ( whole body ) at week 12 
and other measured time points through Week 
52. 

CONFIDENTIAL  Protocol TILD -18-20- 
  
  After a S creening Period of 28 days, all eligible subjects will be randomly allocated  
 
 on Day 1 to receive either tildrakizumab 100 mg or placebo by subcutaneous ( SC) injection  
 
 
 subjects initially randomized to placebo will be switched ov er to receive tildrakizumab 100  mg 
 and s ubjects initially randomized to tildrakizumab 100 mg will continue to 
receive tildrakizumab In order to maintain the blind, subjects in both treatment 
arms will receive matching placebo injections at specified time  points as described in the Schedule o f 
Activities  (SoA) . 
After Week  52 (or early terminat ion of study treatment prior to Week  52), the study treatment should be 
stopped, and the subjects will enter the Observational S afety Follow-up P eriod following the last 
dose of study treatment . During the follow -up period, subjects should continue on study-approved 
concomitant medications only, however  may be placed on other appropriate therapies for safety concerns 
or significant worsening of psoriasis based on the judgment of the Investigator . The s ubjec ts will not receive 
study treatment during the follow -up period. 
The subject’s disease activity (response to study treatment) will be evaluated using the IGA Mod 2011 
(scalp), PSSI, PASI, IGA  (scalp  only) , PGA -S (whole body), IGA Mod 2011 (whole body), Scalp Itch 
Numeric Rating Scale (NRS ), BSA, and Dermatology Life Quality Index ( DLQI ) scores.  
Safety assessments including adverse event (AE) /serious adverse event  (SAE)  monitoring, vital signs, 
physical examination s, electrocardiogram , and laboratory measurements will be performed during the 
study.  
 
 
Number of Investigators and Study Centers:  
Up to   Investigators and study centers (in U nited States  and Australia) are expected to participate in this 
study. 
Number of Subject s: 
The study will randomize approximately 107 subjects per treatment arm (Total N=2 14)  
randomization to either tildrakizumab 100 mg arm or placebo arm.  
Treatment Groups   
 
 
The study consists of a Screening Period   treatment period ( double -blind 
placebo- controlled treatment period followed by  double -blind active treatment period), and  
 Observational  Safety  Follow-up Period. 
Part 1: Double- blind placebo- controlled, where subjects will receive either tildrakizumab  (Arm  A) 
or placebo (Arm  B)  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 18 Part 2: A t Week  16, subjects initially randomized to placebo will be switched over to receive tildrakizumab 
100 mg   Subjects initially randomized to tildrakizumab 100 mg will continue 
to receive active drug  In order to maintain the blind, subjects in both treatment 
arms will receive matching placebo injections a t specified time  points as described in the SoA.  
Part 3: After Week 52 (or early termination of study treatment  prior to Week 52), s ubjects will enter the 
Observational S afety Follow-up P eriod where tildrakizumab treatment will be stopped . 
Statistical methods: 
The primary efficacy endpoint for this study is the proportion of subjects with IGA mod 2011(scalp)  score 
of “clear” and “almost clear” with at least 2-point reduction from baseline at Week  16. The key secondary 
efficacy endpoint s are the proportion of subjects with at least 90% improvement in the PSSI (PSSI90)  from 
baseline at Week 16,  the proportion of subjects with IGA (scalp only) score of “clear” and “almost clear” 
with at least 2 -point reduction from baseline at Week 16 , the proportion of subjects with IGA mod 
2011(scalp) score of “clear” and “almost clear” with at least 2 -point reduction from baseline at Week  12 
and the proportion of subjects with at least 90% improvement in the PSSI (PSSI90) from baseline at 
Week  12. For each en dpoint, the t ildrakizumab 100 mg dose will b e compared with placebo  Both the 
primary and key secondary efficacy endpoints will be analyzed with Cochran -Mantel -Haenszel test 
 
using the Intent- to-treat (ITT) population.    
 
 
 
 
 
 
 
 
  
 Secondary  efficacy  and exploratory endpoints  that are dichotomous  will be analyzed  
in the same  manner  as the primary  efficacy  endpoint  using the ITT population. Continuous  secondary  
efficacy  and exploratory endpoints  will be analyzed  using an MMRM  procedure   
 
 
 
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 20  
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 22   
   
  
  
   
 
             
  
 
   
              
  
  
            
                
                
                
                
                
 
                
                
                
                
 
                
                
                
                

CONFIDENTIAL  Protocol TILD -18-20- 
  
 23    
  
  
   
 
             
  
 
   
              
  
  
            
 
                
 
                
                
                
   
              
                
                
                
 
   
 
 
 
 
 
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 28 Objectives  Endpoints  
• To assess the efficacy of tildrakizumab in subjects 
with moderate to severe scalp psoriasis, as 
measured by the proportion of subjects who achieve IGA ( scalp only ) score of “clear” and 
“almost clear” wit h at least 2 -point reduction from 
Baseline at Week  16. 
• To assess the efficacy of tildrakizumab in subjects with moderate to severe scalp psoriasis, as measured by the proportion of subjects who achieve Investigator Global Assessment ( IGA) 
mod 2011 (scalp) score of “clear” and “almost 
clear” with at least 2 -point reduction from Baseline 
at Week  12. 
• To assess the efficacy of tildrakizumab in subjects 
with moderate to severe plaque psoriasis of the scalp, as measured by the proportion of subjects 
who achieve at least 90% improvement from 
Baseline in the Psoriasis Scalp Severity Index (PSSI) response at Week  12 compared with 
placebo. To assess the efficacy of tildrakizum ab in 
the treatment of moderate to severe plaque 
psoriasis of the scalp compared with placebo as 
measured by scalp surface area involvement at 
Week  16. • The proportion of subjects with IGA mod 2011 
(scalp) score of “clear” and “almost clear” with at 
least 2 -point reduction from Baseline at Week  12 
(key secondary endpoint)  
• The proportion of subjects with at least 90% 
improvement from Baseline in the PSSI at 
Week  12. (Key secondary endpoint).  
• Mean percentage change in PSSI score from 
Baseline to Week  16. 
• The proportion of subjects achieving PSSI  75 at 
Week  16. 
• The proportion  of subjects achieving PSSI  100 at 
Week  16. 
• Mean percentage change in scalp surface area 
involvement from Baseline to Week  16. 
• To assess the effect of Tildrakizumab on IGA mod 
2011 (scalp) and PSSI at other measured time 
points through week 52.  
• To assess the effect of tildrakizumab on IGA 
(scalp only), Scalp Itch NRS, PASI,  PGA- S (whole 
body ), and IGA mod 2011 (whole body),  at week 
12 and other measured time points  through Week 
52. • Change from b aseline in IGA mod 2011 (scalp) 
and PSSI at other measured time points through 
Week 52.  
• Change from Baseline in IGA (scalp only), Scalp Itch NRS, PASI,  PGA-S (whole body ) and IGA 
mod 2011 (whole body), at week 12 and other 
measured time points through Week  52. 
• To assess the time to response.  • Time to 75% reduction in PSSI during the 16-week placebo -controlled treatment period.  
• Time to IGA  mod 2011 (scalp) response during 
the 16 -week placebo -controlled treatment period.  
• To assess the efficacy of tildrakizumab in the improvement of scalp itch as measured by the proportion of subjects achieving a 4 -point 
reduction in Scalp Itch Numeric Rating Scale 
(NRS) score from Baseline at Week  16 compared 
with placebo.  • Proportion of su bjects achieving a 4 -point 
reduction in  Scalp  Itch NRS score from Baseline 
to Week  16. 
• To assess the efficacy of tildrakizumab in the 
treatment of moderate to severe psoriasis • The proportion of subjects achieving PASI  75, 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 30 4.0 STUDY DESIGN 
4.1 Overall  Design  
This is a multicenter,  randomized, double -blind, placebo- controlled study  to assess the efficacy  
and safety  of tildrakizumab in the  treatment  of moderate to severe psoriasis of  the scalp.  The study 
will be conducted in up to 35 study centers across the United States and Australi  
  
 
Approximately 214 subjects ( approximately  107 per arm) with moderate  to severe psoriasis of  the 
scalp will be  enrolled  in the study. Eligible subjects will be randomized to 1 of the 2 arms  
 Arm A: Tildrakizumab 100 mg, SC (n=107) and Arm B: Placebo, SC (n=107).   
   
 
The study will comprise of 3 parts : 
PART 1: Double -blind  Placebo -controlled  (Day 1 to Week  16) 
After  a Screening  Period of  up to 28  days and on Day  1, all  eligible subjects  will be randomized 
 to receive either  tildrakizumab 100 mg  or placebo   
 Subjects should receive the first dose of study treatment  within  24 hours of 
randomization.  
 
PART 2: Double -blind Active  Treatment  Extension (Week  16 to Week  52) 
subjects initially  randomized to placebo  will be switched  over to receive  
tildrakizumab  while s ubjects  initially  randomized to 
tildrakizumab  100 mg will continue to receive tildrakizumab   In order 
to maintain the blind, subjects in both treatment arms will receive matching placebo injections at specified time  points as described in the Schedule of A ctivities  (SoA)  
PART 3
: Observational  Safety Follow -up (Week  52 to Week  72) 
After Week  52 (or early termination of study treatment prior to Week  52), the study treatment 
should be stopped and all subjects, including those who terminated early from Part  1 and 2 will 
enter the Observational Safety F ollow-up P eriod to monitor safety and tolerability   
 following last dose of study treatment . During the follow -up period, subjects should 
continue on study -approved concomitant medications only, however may be placed on appropriate 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 33 5.0 STUDY POPULATION 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 Inclusion Criteria  
Subject s are eligible to be included in the study only if all o f the following criteria apply:  
1. Subjects  should be  18 years  or older at the time of signing the informed consent during the 
Screening visit.  
2. Subjects with a  clinical  diagnosis of chronic plaque psoriasis of at least 6 months  (as determined  
by-subject  intervi ew and confirmation  of diagnosis through physical  examination  by 
Investigator). 
3. Subjects  must  have moderate to severe  plaque psoriasis  of the scalp  at Screening  and at  
Baseline, defined by: 
• Scalp Investigator Global Assessment (IGA mod 2011 (scalp ) of ≥ 3 
• Psoriasis Scalp Severity Index ( PSSI ) score of ≥12  
• ≥30% or scalp  surface area  affected . 
4.  Subject must have moderate to severe plaque psoriasis at Screening and Baseline defined by  
• IGA mod 2011 (whole body)  of at least moderate severity (score of ≥3 on a 5 -pointer 
scale) 
• PASI score of ≥ 12 
• Body Surface Area (BSA) involvement of >10%  
5. Subject s must  be considered  candidate s for systemic  therapy, meaning  scalp  psoriasis  
inadequately controlled  by topical treatments  (corticosteroids),  and/or phototherapy, and/or 
previous  systemic  therapy . 
6. Subject s has a negative evaluation  for tuberculosis  (TB)  within  4 weeks  before initiating study 
treatment , defined as a negative QuantiFERON® test. Subjects with a positive or 2 successive 
indeterminate . QuantiFERON® tests are allowed if they have all of the following : 
• No history of active TB or symptoms of TB. 
• A poste rior-anterior chest radiogram (with associated report available at study center ) 
performed within 3 months of Screening with no evidence of active TB (or of any other 
pulmonary infectious diseases ). 
• If prior latent TB infection (LTBI), must have history of adequate prophylaxis (per local 
standard  of care).  
• If presence of LTBI i s established, then treatment according to local country guidelines 
must have been followed for 4 weeks prior to inclusion in the study. 
A maximum of 2 QuantiFERON® tests are allowed. A re -test is only permitted if the first is  
indeterminate; the result of  the second test will then be used. 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 34 7. Subject s are unlikely to conceive, as indicated  by at least one “Y es” answer  to the following 
questions: 
• Subject is a male.  
• Subject is a female and agrees to abstain from heterosexual activity OR use a  highly 
effective method  of contraception  as per  Appendix 7.  
• Male subjects  with female  partners  of childbearing  potential  who are not using birth 
control as described  above  must  use a barrier  method  of contraception  (eg, condom) if 
not surgically  sterile  (ie, vasectomy).  
• Subject  is a surgically  sterilized  female  or is documented  to be postmenopausal.  
For contraceptive guidance see Appendix 7  
8. For women  of childbearing potential, a negative serum pregnancy test at Screening and a 
negative urine pregnancy test within 24 hours prior to Day  1 and on subsequent visits at which 
study treatment  doses are scheduled . 
9. Subject s must have results of a physical examination within normal limits or clinically 
acceptable limits to the Investigator prior to Day  1. The Investigator is encouraged to consult 
with the Medical Monitor (or appropriate designee) if there are questions regard ing the 
significance of any out- of-range values. 
10. Subjects must be c apable of giving signed informed consent as described in Appendix 2, which 
includes compliance with the requirements and restrictions listed in the ICF and in this protocol. 
5.2 Exclusion Criteria   
Subject s are excluded from the study if any of the following criteria apply:  
1. Subject s who have  laboratory abnormalities  at Screening  including any of the following: 
• Alanine aminotransferase (ALT)  or aspartate aminotransferase (AST)  ≥2.5 × the upper 
limit of normal  (ULN)  
• Creatinine ≥2 × the ULN  
• Serum direct bilirubin ≥1.5 mg/dL  
• White blood cell count <3.0×103/μL 
• Any other laboratory abnormality, which, in the opinion of the Investigator , will prevent  
the subject  from  completing  the study  or will interfere  with the interpretation  of the 
study  results.  
2. Subject s who have  predominantly non-plaque forms  of psoriasis specifically  erythrodermic 
psoriasis,  predominantly pustular psoriasis, medication -induced  or medication -exacerbated  
psoriasis,  or new-onset  guttate  psoriasis.  
3. Women  of ch ildbearing potential  who are pregnant, intend to become pregnant (within  
6 months  of completing the  study ), or are lactating.  
4. Subject s with any infection  or history of recurrent  infection requiring treatment  with systemic  
antibiotics  within  2 weeks  prior  to Screening,  or severe infection  (eg, pneumonia, cellulitis,  
bone or joint infections)  requiring hospitalization  or treatment  with intravenous (IV)  antibiotics  
within  6 weeks  prior  to Screening.  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 35 5. Subject s with any previous use of tildrakizumab or other IL-23/Th-17 pathway  inhibitors, 
including p40, p19 and IL-17 antagonists for psoriasis.  
• Prior  use of TNF -alpha  inhibitors  with a wash -out period of 12  weeks  would be allowed . 
However, the number of subjects with prior  use of TNF -alpha inhibitors  would be 
capped  at 40%  and the analysis  will be stratified  based  on prior  use of  these  biologics. 
6. Subjects with a p ositive human immunodeficiency virus test result, hepatitis B surface  antigen, 
or hepatitis  C virus test result.  
7. Subjects with a p rior malignancy or concurrent  malignancy  (excluding  successfully treated  
basal  cell carcinoma,  squamous  cell carcinoma of the skin in situ, squamous  cell carcinoma of 
skin with no evidence of recurrence within  5 years  or carcinoma in situ of the cervix  that has 
been  adequately  treated).  
8. Subject s who  have received  live viral or bacterial  vaccination  within  4-weeks  prior to Baseline 
or who  intend  to receive live viral or bacterial  vaccination during the study . 
9. Subject s who are currently  participating  in another interventional clinical  study  or has 
participated  in an interventional clinical  study  within  5-half-lives (of the drug)  to wash -out prior 
to randomization  (Subjects  participating  in observational studies  or non-interventional registry  
studies  may be included in the study). 
10. Subject s or a family  member  is among  the personnel of the study center  or Sponsor/designee 
staff directly  involved with this study . 
11. Subjects who have any concomitant medical  con dition  which in the opinion of the Investigator 
could affect  the study outcome or present  an unacceptable  risk. 
12. Subjects who were  hospitalized  due to an acute cardiovascular  event  (such  as myocardial  
infarction , cerebrovascular  accident,  cardiovascular  illness  [eg, angina pectoris ], or 
cardiovascular  surgery  [such as coronary artery bypass  grafting (CABG) ]) within  6 months  
before  Screening . 
13. Subject s who,  in the opinion of the Investigator, will not be a reliable  participant  in the study 
and those who can confound the results of the study. 
14. Subject s who have a  history  of alcohol  or drug  abuse in the previous  year. 
15. Subjects who have high risk of suicidality at the Screening assessment based on Investigator’s 
judgment or, if appropriate, as indicated by a response of “yes” within the last 12 months to 
Questions 4 or 5 in the suicidal ideation section, or any positive response in the behavioral section of the C- SSRS.  
16. Subjects with any other clinically significant laboratory abnormality, which, in the opinion of 
the Investigator, will prevent  the subject  from  completing  the study  or will interfere with  the 
interpretatio n of the study  results.  
5.3 Lifestyle Considerations 
Excessive exposure to sunlight should be avoided during the study. Subjects should avoid use of tanning booths or other ultraviolet light sources for the duration of the study. 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 36 5.4 Screen Failures  
Screen failures are defined as subject s who consent to participate in the clinical study but are not 
subsequently entered in the study . A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure subject s to meet the Consolidated Standards of Reporting 
Trials  publishing requirements and to respond to queries from r egulatory authorities. The minimal  
information includes demography, screen failure details, eligibility criteria, and any  SAE . 
Individuals who do not meet the criteria for participation in this study (screen failure) may  be 
rescreened  at the discretion of the Investigator for up to 2 additional times, with a minimum of 
2 we eks between each re screening. When a subject is re screened, all S creening procedures will be 
repeated .   
Note:   If the original ICF was signed within 30 days of the rescreening visit, a new ICF does not 
need to be completed. 
Rescreened subject s should not be assigned the same subject  number as f or the initial Screening. 
Any subject who is started on prophylactic treatment for latent  TB during the Screening P eriod 
may be randomized 4 weeks after initiation of treatment without need for rescreening.  
  

CONFIDENTIAL  Protocol TILD -18-20- 
 
37 6.0 STUDY TREATMENT 
Study treatment is defined as an y investigational treatment(s ), marketed product(s), placebo, or 
medical device (s) intended to be administered to a subject  according to the study protocol. 
The study treatment in this study is tildrakizumab and placebo.  
The study arms will receive study 
treatment  during the course of the study as follows: 
Arm A: 
oTildrakizumab 100 mg  SC injections  
oPlacebo  injections  
Arm B: 
oPlacebo  injections  
oTildrakizumab 100 mg  SC injections
  
 
  
Study Treatment Name:  Tildrakizumab  Placebo  
  
 
 
 
 
  
 
 
 
 
Unit Dose S trength /Dosage 
Level: 100 mg - 
Route of Administration Subcutaneous ( SC) SC 
  
 
 
 
  
 
 
 

CONFIDENTIAL  Protocol TILD -18-20- 
 
38    
  
 
   
6.2 Preparation/Handling/Storage /Accountability  
1.The Investigator or designee must confirm appropriate temperature conditions have been
maintained during transit for all study treatment received and any discrepancies are reported
and resolved before use of the study treatment.
2.Only subject s enrolled in the study may receive study tr eatment and only authorized study
center  staff may supply or administer the study treatment.  All study treatments must be stored
in a secure, environmentally controlled, and monitored (manual or automated) area in
accordance with the labeled  storage condit ions with access limited to the Investigator and
authorized study center  staff .
3.
Study treatment  experiencing temperature  excursions outside this temperature  should
be quarantined and can only be released  for subject use after consultation with the Sponsor.
4.The Investigator , institution, or the head of the medical institution (where applicable) is
responsible for study treatment accountability, reconciliation, and record maintenance ( ie,
receipt, reconciliation , and final disposition records).
5.Further guidance and information for the final disposition of unused study treatment will be
provided by the study center monitor.
The Investigator , a member of the study center  staff, or a hospital pharmacist must maintain an 
adequate record of the receipt and distribution of all study treatment  using the Drug Accountability 
Form.  
6.3 Measures to Minimize Bias: Randomization and Blinding  
All subjec ts will be centrally assigned   to receive either  tildrakizumab  100 mg or 
placebo  using an Interactive Web Response System ( IWRS). Before the study is initiated, the log 
in information and  directions for the IWRS will be provided to each study center. 
This is a double -blind study with limited access to the randomization code. Tildrakizumab and 
placebo will be identical in physical appearance.  
  
 
Study treatment will be  dispensed at the s tudy visits summarized in the SoA    
Returned study treatment should not be re-dispensed to the subjects. 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 39  In case of an emergency, the 
Investigator has the sole responsibility for determining if unblinding of a subject’s treatment 
assignment is warranted. Subject safety must always be the first consideration in making such a determination. If the Investigator decides that unblinding is warranted, the Investigator should make every effort to contact the Spo nsor prior to unblinding a subject’s treatment assignment 
unless this could delay emergency treatment of the subject. If a subject’s treatment assignment is unblinded, the Sponsor must be notified within 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation and electronic case 
report form ( eCRF ), as applicable.
 
A designated member of the Sponsor’s safety team will be unblinded for any S uspected 
Unexpected Serious A dverse Reactions , for regulatory reporting purposes. Unblinding is for 
regulatory reporting purpose only   
6.4 Study Treatment Compliance 
The prescribed dosage, timing, and mode of administration may not be changed. Any departures from the intended regimen must be recorded in the e CRFs.  
 
Study treatment accountability and subject compliance will be documented througho ut the 
treatment periods  using study -specifi c study treatment dispensing record forms. 
If a subject does not receive the scheduled dose, every effort should be made to administer the dose as soon as possible. 
6.5 Concomitant Therapy  
Any medication or vaccine (including over -the- counter or prescription medicines, vitamins, and/or 
herbal supplements) that the subject is receiving at the time of enrollment or receives during the 
study must be recorded on the eCRF along with:
 
• Reason for use.  
• Dates of administration including start and end dates. 
• Dosage information including dose and frequency. 
In addition, all prior medications used to treat the disease conditions and any other medications taken within 6 months prior to enrollment must be recorded in the eCRF.   
The Medical Monitor should be contacted if there are any questions regarding concomitant or prior 
therapy.  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 40  
Other
 concomitant medication may be considered on a case -by-case basis by the Investigator in 
consultation with the Medical Monitor if required . 
6.5.1 Rescue Medicine 
Not applicable.  
  
  
 
  
 
  
  
  
  
 
  
 
 
 
 
 
6.6 Dos
e Modification 
No dose modification is allowed in this study. Study treatment can be interrupted temporarily or 
permanently if deemed necessary as per the Investigator’s discretion.  
6.7 Treatment after the End of the Study  
The Sponsor will not provide any study treatment to the subjects during the Observational Safety 
Follow-up Period. Patient care should not differ from what is normally expected for subjects with psoriasis.  
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 41 7.0 DISCONTINUATION OF STUDY TREATMENT AND SUBJECT 
DISCONTINUATION/WITHDRAWAL   
7.1 Discontinuation of Study Treatment   
Subjects  may voluntarily discontinue study treatment  for any reason at any time and enter the 
wash -out period, or completely withdraw from the study  Subjects who 
consent to enter the wash -out period will undergo the Week 52 (EoT ) assessment a minimum of 
4-weeks after admini stration of the last dose of study treatment.  
At any time durin g Part  1 or Part  2 of the study, the Investigator should discontinue study treatment  
of a given subject if, on balance, he/she believes that continuation would be detrimental to the 
subject’s well -being.  
The study treatment  must be discontinued under the following circumstances and the further steps 
need to be discussed with the Medical Monitor: 
• An SAE, drug reaction or complication, or an unacceptable AE, whether attributed to study treatment or not, that precludes continuation of treatment with study  treatment . This 
includes the development of allergic reactions or the development of other potentially serious drug reactions to medication required by the protocol 
• Diagnosis of malignancy (except basal or squamous cell carcinoma of skin) during study 
(at dis cretion of the subject and Investigator) 
• Subjects who develop suicidal behavior 
• Evidence of pregnancy 
• Withdrawal of informed consent 
• Lost to follow-up 
• Significant non-compliance of the subject with study procedures 
• Decision of the Sponsor to terminate the subject, study center, or the study. 
 
Subjects who withdraw from the study at any part will undergo the Week  52 (EoT)  assessments. 
Patient related outcome  (PRO) measurement should be obtaine d immediately after subject 
withdrawal.  Week  52 (EoT)  assessments should be conducted a minimum of 4- weeks after 
administration of the last dose of study treatment.  
See the SoA  for data to be collected at the time of treatment discontinuation and 
follow-up and for any further evaluations that need to be completed . 
7.1.1 Temporary Discontinuation  
Study treatment can be interrupted temporarily  in case of :  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 42 • Clinically important laboratory abnormalities . 
• Subjects who develop suicidal ideation. 
• Other intercurrent illnesses or major surgery . 
• Use of prohibited treatment. 
• Any other protocol deviation that results in a significant risk to the subject’ s safety . 
• Sponsor decision. 
The Medical Monitor should be informed. Re -starting of study treatment at the next scheduled 
administration study visits can be done after discussion with the Medical Monitor. 
7.2 Subject Discontinuation/ Withdrawal from the Study  
Subjects may voluntarily withdraw consent to participate in the study for any reason at any time.  
Withdrawal of consent occurs when a subject does not want to participate in the study anymore 
and does not want to attend any further visits or assessments, have further study -related contact, 
or allow analysis of already obtained biologic material.  
If a subject withdraws consent, the Investigator must make every effort to determine the primary reason for this decision and record this information on the treatment disposition eCRF page. If the subject decides to completely withdraw from the study (refuses any further study participation or contact), all study participation for that subject will cease and data to be collected at subsequent visits will be considered missing. The study treatment must be discontinued, and no further 
assessments conducted. Further attempts to contact the subject are not allowed unless safety findings require communication or follow-up. 
However, for safety reasons, Week 52 (EoT) assessments should be conducted for subjects 
withdrawing during Part 1 or 2, if the withdrawn subject is willing to undergo the assessments. For subjects withdrawing during Part 3 and willing to undergo final assessments, the  Week  72 (EoS) 
assessments should be c onducted at least 4 weeks after their last visit.  
The app ropriate personnel from the study center  and CRO  will assess whether the study treatment 
should be discontinued for any subject whose treatment code has been broken inadvertently for any reason.  
The Investigator must also contact the IWRS to register the subject’s discontinuation from the 
study treatment.  
7.3 Lost to Follow-up 
A subject  will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study center. 
The following actions must be taken if  a subject  fails to return to the study center  for a required 
study visit: 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 43 • The study center  must attempt to contact the subject and reschedule the m issed visit as soon 
as possible and c ounsel the subject  on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in the 
study.  
• Before a  subject  is deemed lost to follow -up, the Investigator  or designee must make every 
effort to regain contact with the subject  (where possible, 3 telephone calls and , if necessary , 
a certified letter to the subject ’s last known mailing address or local equivalent methods). 
These contact attempts should be documented in the subject ’s medical record . 
• Should the subject  continue to be unreachable, he/she will be considered to have withdrawn 
from the study.  
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 45 8.1.1 Assessments for Scalp :  
8.1.1.1 Investigator Global Assessment (IGA) mod 2011 rating scale (Scalp)  
The IGA mod 2011 is a scale that is  static  
 
 This scale met the evidence standard  
for pivotal trials, and has supported previous product labeling claims        
 
8.1.1.2 Investigator Global Assessment ( Scalp  only) 
The  IGA score is a useful clinician assessment of scalp lesions based on thickness, 
erythema, and scaling that is here retained as a secondary endpoint  
 
 
  
  
 
  
  
8.1.1.5 Pso
riasis Scalp Severity Index  (PSSI)  
The PSSI  is a modification of the PASI to specifically asses s severity of scalp disease. The PSSI 
use a  scale to grade the 3 clinical parameters  in the same 
way as the PASI, but for scalp only .  
8.1.2 Ass
essments for Whole Body:  
8.1.2.1 Investigator Global Assessment (IGA) mod 2011 rating scale (whole body) 
The IGA mod 2011 is a scale   

CONFIDENTIAL  Protocol TILD -18-20- 
  
 46 This  scale met the evidence standard 
for pivotal trials, and has supported previous product labeling claims  
 
    
 
8.1.2.2 Physician Global Assessment of Skin (Whole body ) 
The PGA -S is a  useful clinician assessment of psoriasis lesions on 
the skin based on degree of erythema, thickn ess, and scale averaged over the entire body.  
 
8.1.2.3 Ps
oriasis Area and Severity Index  
Psoriasis Area and Severity Index  will be used to determine the treatment response (PASI  75, PASI 
90, and PASI  100) in subjects with scalp  psoriasis.  
8.1.2.4 Bo
dy Surface Area  
Body Surface Area is a commonly used measure of severity of skin disease. It is defined as the 
percentage of the total BSA  affected by psoriasis , it represents the area of affected scalp.     
 
8.1.3 Dermatology L ife Quality Inde x 
The DLQI q uestionnaire will be used to assess treatment response on the subject’s quality of life . 
The aim of this questionnaire is to measure how much the skin condition has affected the subject’s  
life during the previous week.  
  
The questionnaire is self- explanatory and handed to the subject who is asked to fill it 
in without the need for a detailed explanation   
8.2 Safety  Assessments  
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
  • A central laboratory will be used to perform all laboratory tests  except urine pregnancy 
dipstick which will be assessed by the center staff . However, local laboratory tests will be 
allowed in the event that the central laboratory results will not  be available immediately 
and the Investigator needs to take an immediate decision for any safety concerns based on 
the laboratory results.  
• The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the e CRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those that are not associated with the underlying disease, unless judged by the Investigator  to be more severe than expected for the subject’s condition. 
• All laboratory tests with values considered clinically significantly abnormal during participation in the study  including the subject’s last EoS visit should be repeated until the 
values return to normal or Baseline or until stabilized or are no longer considered clinically 
significant by the Investigator or Medical Mo nitor. 
If such values do not return to normal/ Baseline within a period of time judged reasonable by the 
Investigator, the etiology should be identified, if possible and the Sponsor notified. 
All protocol -required laboratory assessments,  must be conducted in 
accordance with the Laboratory M anual   
8.3 Adverse Events  
The safety and tolerability of subjects will be assessed by the incidence of treatment -emergent 
adverse events ( TEAEs ), laboratory test results, vital signs, ECGs , and physi cal examination 
findings. The definitions of an AE or SAE can be found in Appendix 4.  
The Investigator will document all AEs in the subject’s source document and eCRF. All entries 
should contain an event term, date of onset, date of resolution, severity, action taken, outcome, relationship to study treatment, and a seriousness assessment.  
8.3.1 Time Period and Frequency for Collecting AE and SAE Information  
Any relevant observations made before the end of the Screening and Baseline visit (prior to first dose of study treatment) are to be recorded on the AE eCRF, but will not be considered TEAEs and will be reported separately from TEAEs. Any relevant observations made after the first dose 
of study treatment will be recorded as an AE in the subject’s AE eCRF  
  
For t
he purposes of this study, any detrimental change in the subject’s condition, 
after the first dose of study treatment and up to completion of the EoS visit, should be considered 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 50 an AE . For those subjects who may withdraw during the Observational Safet y Follow -up P eriod  
or wash -out period, at least 2 attempts should be made to collect the AEs. 
A hospitalization planned by the subject prior to signing the ICF is considered a therapeutic 
intervention and not the result of a new SAE and should be recorded as medical history. If the planned hospitalization or procedure is executed as planned, the record in the subject’s medical history is considered complete. However, if the event/condition worsens during the study, it must be reported as an AE . 
Medical occu rrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the AE section of the e CRF , however will not be considered as TEAEs.  
All SAEs will be recorded  and reported to the CRO  within 24 hours, as indi cated in Appendix 4. 
The Investigator will submit any updated SAE data to the CRO  within 24  hours of it being 
available.  The Investigator is responsible for informing the Ethics Committee of the SAE as per 
local requirements.  All AEs/SAEs have to be reported to the Sponsor, whether or not considered 
causally related to the study treatment or to the study procedures.  
Investigators are not obligated to actively seek AE or SAE after conclusion of the study participat ion. However, if the Investigator learns of any SAE, including a death, at any time after 
a subject  has been discharged from the study, and he/she considers the event to be reasonably 
related to the study treatment or study participation, the Investigator must promptly notify the CRO . 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting SAE reports are provided in Appendix 4. 
8.3.2 Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended and 
non-leading verbal questioning of the subject  is the preferred method to inquire about 
AE occurrences .  
8.3.3 Follow- up of AEs and SAEs  
After the initial AE/SAE report, the Investigator  is required to proactively follow each subject  at 
subsequent visits/contacts. All SAEs , and non- serious AEs of special interest (as defined in  Section 
8.3.6) , will be followed until resolution, stabilization, the event is otherwise explained, or the 
subject  is lost to follow -up (as defined in Section 7.3). Further information on follow -up 
procedures is given in Appendix 4.  
8.3.4 Regulatory Reporting Requirements for SAEs  
All SAEs must be reported according to ICH GCP or local regulations, applying the regulation 
with the stricter requirements. The report will contain as much available information concerning the SAE to enable the Sponsor’s designated pharmacovigilance personnel/ CRO to file a report, 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 51 which satisfies regulatory reporting requirements. The SAE report will be notified by Investigator 
within 24- hours of his/her awareness to the Sponsor’s designated pharmacovigilance 
personnel/CRO. These timelines apply to initial reports of SAEs and to all follow-up reports. 
All SAEs will be recorded on the SAE report form in the eCRF and source documents. 
The following minimum information must be included in the SAE form: 
• Name, address and telephone number of the reporting Inves tigator  
• Study treatment  details  
• Subject identification number, initials, sex and date of birth 
• Description of the SAE, measures taken and outcome 
Relevant pages from the eCRF  may be provided in parallel (eg , medical history, concomitant 
drugs). Additional documents may be provided by the Investigator, if available (eg , laboratory 
results, hospital report, autopsy report).  
The Investigator must respond to any reque st for follow -up information (eg , additional 
information, outcome, final evaluation, other records where needed) or to any question the 
Sponsor’s designated pharmacovigilance personnel/CRO may have on the SAE. This is necessary to ensure prompt assessment of the event by the Sponsor’s designated pharmacovigilance personnel to allow the Sponsor to m eet strict regulatory timelines associated with expedited safety 
reporting obligations. 
8.3.5 Pregnancy  
Pregnancy itself is not regarded as an AE unless  there is suspicion that the study treatment may 
have interfered with the effectiveness of a contraceptive med ication. If a pregnancy is report ed for 
a subject, no further study treatment  will be administered to this subject and the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, normal birth or congenital 
abnormality) must be followed up and documented. Follow -up should be performed up to delivery 
and examination of the new born, after which a follow -up report should be sent with any new 
information regarding the pregnancy and the outcome of the birth. 
The pregnancy shall be followed ever y 3 months during pregnancy until its outcome and 1 month 
post- delivery. If there are abnormalities present at delivery, the newborn will be  followed for an 
appropriate period, or up to 3 months, to assess the functional and health status of the child. All congenital abnormalities/birth defects should be classified as SAEs. Spontaneous miscarriages 
should also be reported and handled as SAEs. Elective abortions without complications should not be handled as SAEs but should be reported as a follow-up report for the pregnancy. All outcomes of pregnancy must be reported to the Sponsor on a Pregnancy Outcomes Report Form. 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 52 Pregnancy outcomes must be collected for the female partners of any males who took study 
treatment in this study. Consent to report information regarding these pregnancy outcomes should be obtained from the female partner. 
Pregnancies must be reported to Novella Clinical Pharmacovigilance and Safety Services using 
the reporting details provided in Appendix 4 within 24 hours of becoming aware of the pregnancy. 
8.3.6 Adverse Events of S pecial Interest  
The events of severe infections,  injection site reactions (e.g. pain, edema, erythema),  malignancies 
(including non- melanom a and melanoma skin cancer), Major Adverse Cardiovascular Events , and 
study treatment - related hypersensitivity reactions ( see Appendix 5) will be identified as adverse 
events of special interest ( AESIs ) for summarizing in this study. Major Adverse Cardiovascular 
Events include non- fatal stroke, non- fatal myocardial infarction and cardiovascular death. An 
AESI must be reported as if it were an SAE.  
8.3.7 Events of Clinical Interest  
An Event of Clinical Interest (ECI) is a non- serious AE or occurrence that is designated to be of 
special interest and must be reported to the Sponsor as though it were an SAE. 
 
  
 
    
  
 
  
8.4 Treatment of Overdose  
A drug overdose is defined as the accidental or intentional use of a drug or medicine or an administration error in an amount that is  higher than is normally used.   
Overdose in this study is specificall y defined as any dose greater than the intended protocol dose 
In case of overdose, it is recommended that the subject be monitored for any signs 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 53 or symptoms of adverse reactions or effects and appropriate symptomatic treatment be instituted 
immediatel y. 
8.5 Pharmacokinetics  
Pharmacokinetic parameters are not evaluated in this study.  
8.6 Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study.  
8.7 Genetics  
Genetics are not evaluated in this study.  
8.8 Biomarkers  
Biomarkers a re not evaluated in this study.  
8.9 Health Economics or Medical Resource Utilization and Health Economics 
Health Economics/Medical Resource Utilization  and Health Economics  parameters are not 
evaluated in this study. 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 55  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
9.3  Pop
ulations for Analyses 
For purposes of analysis, the analysis sets in Table 3 are defined.  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 56 Table 3 Analysis Sets 
Analysis Set  Description  
Intent- to-Treat (ITT)  All randomized subjects who have received  dose of study 
treatment   
 
Subjects will be analyzed according to their planned treatment 
assignment.  
Per Protocol Set (PPS)  All subjects in the ITT  population who complete the  placebo -
controlled treatment  
 
 
 
 
 
Safety  Analysis Set  (SAS) All randomized subjects who receive  dose of study 
treatment .  Subject s will be analyzed according to the treatment they 
actually received.  Safety endpoints will be analyzed descriptively 
based on the SAS. 
9.4 Statistical Analyses 
The statistical analysis will be performed using statistical analysis system ( SAS®) Version  9.3 or 
higher if available. All details regarding the statistical analysis and the preparation of tables, 
listings and figures will be described in the S tatistical Analysis Plan ( SAP). The SAP will be 
developed and finalized before database lock after the com pletion  of the  
placebo -controlled treatment period. This section is a summary of the planned statistical analyses 
of the primary and secondary endpoints. 
The following descriptive statistics will be used as applicable to summarize the study data un less 
otherwise specified:  
• Continuous variables: sample size (n), mean, standard deviation ( SD), median, minimum 
(min) , and maximum (max) . 
• Categorical variables: frequencies and percentages . 
Unless otherwise specified, “Baseline” is defined as the last observed value of the parameter of 
interest prior to the first intake of study  treatment (this includes unscheduled visits).   
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 60 tabulated for each treatment arm . Commonly occurri ng TE AEs,  
 in either treatment arm , will be summarized using descriptive statistics.  
The safety  of tildrakizumab  will be evaluated by  and reported as the percentage of subjects for 
the following TEAEs: 
• Incidence, seriousness and severity  of all AEs , death cases and discontinuations from the 
study. 
• Percentage of subjects with severe infections, defined as any infection meeting the 
regulatory definition of a serious adverse event, or any infection requiring IV antibiotics whether or not reported as a serious event as per the regulatory definition. 
• Percentage of subjects with malignancies (excluding carcinoma in situ of the cervix).  
• Percentage of subjects with non- melanoma skin cancer.  
• Percentage of subjects  with melanoma skin cancer.  
• Percentage of subjects with MACE   
• Percentage of subjects with study treatment- related hypersensitivity reactions (eg,  
anaphylaxis, urticaria, angioedema, etc).  
• Percentage of subjects with injection site reactions (eg, pain, erythema, edema, etc) . 
9.4.2.2 Physical Examinations, 12-Lead ECG, Vital Signs and Clinical Safety 
Laboratory Tests (Hematology, Biochemistry, and U rinalysis)  
Summaries and listings of data for physical examination findings, vital signs, hematology, 
biochemistry , and urinalysis laboratory tests will be presented. Appropriate descriptive statistics 
will be summariz ed for the observed value at each scheduled assessment and for the 
corresponding change from Baseline. 
For hematology and bio chem istry tests, listings of subject data will also flag up any abnormal or 
out-of- range values. Clinically significant changes in the lab oratory test parameters will be 
summariz ed and listed. Hematology and clinical laboratory data will be reported in System 
International units. 
Descriptive statistics will be used to present the safety outcomes including, physical examination 
results, weigh t, body mass index, 12-Lead ECG, vital signs measurements, and cl inical 
laboratory test results.  
Change from Baseline will also be summariz ed for vital signs measurements and  clinical 
laboratory test results.  
All ECG data results (normal/abnormal) will be  summarized using frequency and percentages. 
Clinically significant abnormalities will be presented in by -subject listings.  

CONFIDENTIAL  Protocol TILD -18-20- 
  
    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
  
  
  
  
  
  
  
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 65   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 66 APPENDIX 2: REGULATORY, ETHICAL AND STUDY OVERSIGHT 
CONSIDERATIONS  
Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines . 
o Applicable International Council for Harmonisation Good Clinical Practice ( ICH 
GCP ) Guidelines. 
o Applicable laws and regulations. 
• The protocol, protocol amendments, informed consent form ( ICF), Investigator Brochure, 
and other relevant documents ( eg, advertisements) must be submitted to an IRB/IEC by 
the Investigator and reviewed and approved by the Institutional Review Board 
(IRB)/Independent Ethics Committee ( IEC) before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC and regulatory authority approval, 
when applicable, before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to subjects.  
• The Investigator will be responsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC . 
o Notifying the IRB/IEC of serious adverse events ( SAEs ) or other significant safety 
findings as required by IRB/IEC procedures. 
o Providing oversight of the conduct of the study at the study center and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the IRB/IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations . 
o After reading the protocol, each Investigator will sign the protocol signature page and 
send a copy of the signed  page to the Sponsor or representative ( see Appendix 20). 
o The study will not start at any study center  at which the Investigator has not signed 
the protocol. 
Financial Disclosure  
Investigators and sub- Investigators will provide the Sponsor with suf ficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 67 responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 
Insurance  
Sponsor will provide insurance in accordance with local guidelines and requirements as a minimum for the subjects in this study. The terms of the insurance will be kept in the study files.  
Informed Consent Process  
• The Investigator or his/her representative will explain the nature of the study to the 
subject  or his/her legally authorized representative and answer all questions regarding the 
study.  
• Subject s must be informed that their participation is voluntary. Subject s or their le gally 
authorized representative  will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health 
Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, 
and the IRB/IEC or study center .  
• The medical record must include a statement that written informed consent was obtained 
before the subject  was entered in the study and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF. 
• Subject s must be re-consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the subject  or the subject’s legally authorized 
representative.  
• A subject who is rescreened is not required to sign another ICF if t he rescreening occurs 
within 30 days from the previous ICF signature date. 
Data Protection  
• Subject s will be assigned a unique identifier by the Sponsor . Any subject  records or 
datasets that are transferred to the Sponsor will contain the identifier only; subject  names 
or any information which would make the subject  identifiable will n ot be transferred.  
• The subject  must be informed that his/her personal study- related data will be used by the 
Sponsor in accordance with local data protection law. The level of disclosure must also 
be explained to the subject .  
• The subject  must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor , by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities. 
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
   
  
  
 
  
  
  
   
  
   
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
Qual
ity Control and Quality Assurance  
 
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 69  Quality control will be ap plied  to each stage of data 
handling. 
The following steps will be taken to ensure the accuracy, consistency, completeness, and 
reliability of the data:  
• Central laboratories for clinical laboratory parameters.  
• Study c enter  Initiation visit. 
• Early study center visits post-enrollment. 
• Routine study center  monitoring. 
• Ongoing study center communication and training. 
• Data management quality control checks . 
• Continuous data acquisition and cleaning. 
• Internal review of data. 
• Quality control check of the final clinical study report (CSR).  
In addition, Sponsor may conduct periodic audits 
of the study processes, including, but not limited to study center, central laboratories, vendors, clinical database, and final CSR. When audits are conducted, access must be authorized for all study-related documents including medical history and concomitant medication documentation 
to authorized Sponsor’s representatives and regulatory authorities. 
Monitoring 
Sponsor has engaged the services of a contract research organization ,  to perform all 
monitoring functions within this clinical study . monitors will work in accordance with 
SOPs . The monitor will establish and maintain regular contact between the Investigator 
and Sponsor. 
The monitor will evaluate the competence of the  study center, informing Sponsor about any 
problems relating to facilities, technical equipment, or medical staff . During the study, the 
monitor will check that written infor med consent has been obtained from all subjects  correctly 
and that data are recorded correctly and completely . The monitor is also entitled to compare 
entries in the eCRF s with corresponding source data and to inform the Investigator of any errors 
or omissions. The monitor will also  assess and  control adherence to the protocol and ICH/GCP 
guidelines at the study center . The monitor will arrange for the supply of study treatment,  ensure 
proper study treatment dispensing/accountability, and appropriate storage conditions are 
maintained.  
Monitoring visits will be conducted according to all applicable regulatory requirements and 
standards. Regular monitoring visits will be made to each center while subjects  are enrolled in 
the study.  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 70 During monitoring visits, a ll entries in the eCRF s will be compared with the original source 
documents (source data verification). For the following and all other items, this check will be 
100%: 
• Subject  identification number. 
• Subject  consent obtained. 
• Subject  eligibility criteria (inclusion and exclusion criteria) . 
• Efficacy variables  (not directly entered into PRO). 
• Safety variables.  
• Medical record of AE.  
Quality Management 
A system should be implemented to manage quality throughout all stages of the study process 
with the focus on study activities essential to ensuring human subject protection and the 
reliability of study results. The methods used to assure and control the quality of the clinical 
study should be proportionate to the risks inherent in the tr ial and the importance of the 
information collected. All aspects of the study should be operationally feasible and should avoid 
unnecessary complexity, procedures, and data collection.  
During protocol development, processes and data that are critical to ensure human subject 
protection and the reliability of trial results should be identified. Risks should be considere d at 
both the system level (eg , standard operating procedures, computerized systems, personnel) and 
clinical trial level (eg , trial design, data collection, informed consent process). The approach used 
to reduce risk to an acceptable level should be proportionate to the significance of the risk. 
Predefined quality tolerance limits should be established, taking into consideration the medical 
and statistical characteristics of the variables as well as the statistical design of the trial, to 
identify systematic issues that can impact subject safety or reliability of trial results. Detection of 
deviations from the predefined quality tolerance limits  should trigger an evaluation to determine 
if action is needed.  
Quality management activities should be documented and communicated to those who are involved in or affected by such activities, to facilitate risk review and continual improvement 
during clinical trial execution.  
Data Management/Coding 
 
 
Electronic data capture will be used for this study, mean ing that all eCRF data will be entered in 
electronic forms at the study center s. Data collection will be completed by authorized study 
center staff designated by the Investigator . Appropriate training and security measures will be 

CONFIDENTIAL  Protocol TILD -18-20- 
  
  completed with the Invest igator  and all designated study center staff prior to the study being 
initiated and any data being entered into the system for any study subjects . 
All data must be entered in English. The eCRFs should always reflect the latest observations on 
the subjects  participating in the study. Therefore, the eCRFs are to be completed as soon as 
possible during or after the subject ’s visit. To avoid inter-observer variability, every effort should 
be made to  ensure that the same individual who made the initial Baseline determinations 
completes all efficacy and safety evaluations. The Investigator must verify that all data entries in 
the eCRFs are accurate and correct. If some assessments are not done, or if certain information is 
not available or not applicable or unknown, the Investigator  should indicate this in the eCRF. 
The Investigator will be required to electronically sign off on the clinical data  when all the data 
is clean prior to database lock. 
The monitor will review the eCRFs and evaluate them for completeness  and consistency. The 
eCRF will be compared with the source documents to ensure that there are no discrepancies 
between critical data. The monitor cannot enter data in the eCRFs. All entries, corrections and 
alterations are to be made by the responsible In vestigator or his/her designee . If additional 
corrections are needed, the responsible monitor or Data Manager will raise a query in the EDC 
application . The appropriate study center staff will answer queries sent to the Investigator. This 
will be audit trailed by the EDC application meaning that the name of investigational staff, time , 
and date stamp are captured.  
The eCRF is essentially considered a data entry form and should not constitute the original (or 
source) medical records unless otherwise specifie d. Source documents are all documents used by 
the Investigator or hospita l that relate to the subject’s medical history, that ve rify the existence of 
the subject, the inclusion and exclusion criteria and all records covering the subjec t’s 
participation in the study. They include but are not limited to laboratory notes, ECG results, 
memoranda, pharmacy dispensing records, subject files, etc.  Source data should be attributable, 
legible, contemporaneous, original, accurate, and complete. A ny changes to the source 
documents or cancellations should be signed and initialed with date. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary (eg, via an audit trail) . 
The Investigator is responsible for maintaining source documents. These will be made available 
for inspection by the study monitor at each monitoring visit. The Investigator must submit a completed eCRF for each subject who  is screened and enrolled in the study regardless of 
duration. All supportive documentation submitted with the eCRF, such as laboratory or hospital records, should be clearly identified with the study and subject number. Any personal information, including subject name, should be removed or rendered illegible to prese rve 
individual confidentiality. 

CONFIDENTIAL  Protocol TILD -18-20- 
  
  User Roles and Responsibilities:  
Once clinical data of the eCRF have been submitted to the central server, corrections to the data 
fields will be audit trailed, meaning that the reason for change, the name of the person who 
performed the change, together with time and date will be logged. Roles and rights of the study center staff responsible for entering the clinical data into the eCRF will be determined in  
advance.  
Electronic  CRF  records will be automatically appended with  the identification of the creator, by 
means of their unique User ID. Specified records will be electronically signed by the Investigator 
to document his/her review of the data and acknowledgement that the data are accurate. This will be facilitated by mea ns of the Investigator’s unique User ID and password; date and time stamps 
will be added automatically at time of electronic signature.  
Data Handling and Record Keeping  
The Investigator must maintain essential study documents (protocol and protocol amendments, completed eCRFs, signed ICFs , relevant correspondence, and all other supporting 
documentation). The study center should plan on retaining such documents for approximately 
15 years after study completion. The study center should retain such documents until at least 
2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2  years after the 
formal discontinuation of clinical development of the study treatment. These documents should be retained for a longer period if required by the applicable regulatory requirements or the hospital, institution, or private practice in which the study is being conducted. Subject 
identification codes (subje ct names and corresponding study numbers) will be retained for this 
same period of time . These documents may be transferred to another responsible party, 
acceptable to Sponsor, who agrees to abide by the retention policies. Written notification o f 
transfer  must be submitted to Sponsor. The Investigator  must contact Sponsor prior to disposing 
of any study records. 
Direct Access to Source Documents  
The Investigator will prepare and maintain adequate and accurate source documents to record all 
observations and other pertinent data for each subject  randomized into the study. 
The Investigator will allow Sponsor,  and authorized regulatory authorities to have di rect 
access to all documents pertaining to the study, including individual subject  medical records, as 
appropriate. Such information must be kept confidential and must have locked facilities that 
allow for th is. Subject identification number will be record ed on all documents related to the 
study.  
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 73 Study and Study Center Closure  
The Sponsor designee reserves the right to close the study center  or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study center s will be closed upon study 
completion. A study center  is considered closed when all required documents and study supplies 
have been collected and a study center  closure visit has been performed. 
The Investigator may initiate study center  closure at any ti me, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study center  by the Sponsor or Investigator may include but 
are not limited to: 
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the Sponsor’s procedures, or GCP guidelines. 
• Inadequate recruitment of subject s by the Investigator. 
• Discontinuation of further study treatment development. 
Publication Policy  
The data generated by this study are confidential information of the Sponsor. The Sponsor will make the results of the study publicly available. The publication policy with respect to the 
Investigator and study center will be set forth in the Clinical Trial Agreement.  
 
 
 
  
 
  
 
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 74  
  
  
 
  
 
 
 
  
  
 
  
 
  
 
  
 
  
   
  
 
  
  
  
 
  
   
 
   
  
  
  
  
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 75  
  
 
  
  
  
  
  
  
   
  
   
  
 
  
 
  
 
 
 
  
 
    
  
  
  
  
 
  
 
    
 
 
 
  
 
 
 
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 77 APPENDIX 4: ADVERSE EVENTS: DEFI NITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING  
Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a patient or subject, temporally associated with the use 
of study treatment, whether or not considered related to the study treatment.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of 
study treatment.  
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from 
Baseline, considered clinically significant in the medical and scientific judgment  of the Investigator 
(ie, not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of ei ther study treatment or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self -harming intent. Such overdoses should be reported 
regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be  reported as AE or SAE if they fulfill the 
definition of an AE or SAE.  
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 78 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the Investigator to be more severe than 
expected for the subject’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe than expected for the su bject’s condition.  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).  
• Antic ipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at the 
start of the study that do not worsen.  
• Pregnancy itself is not regarded as an AE unless there is suspicion that the study treatment may have 
interfered wit h the effectiveness of a contraceptive medication. If a pregnancy is reported for a subject, 
no further study treatment will be administered to this subject and the outcome of all pregnancies 
(spontaneous miscarriage, elective termination, normal birth or congenital abnormality) must be followed up and documented. Follow -up should be performed up to delivery and examination of the 
newborn, after which a follow -up report should be sent with any new information regarding the 
pregnancy and the outcome of the b irth. 
• All congenital abnormalities/birth defects should be classified as SAEs. Spontaneous miscarriages should also be reported and handled as SAEs. Elective abortions without complications should not be handled as SAEs but should be reported as a follow -up report for the pregnancy. All outcomes of 
pregnancy must be reported to the Sponsor on a Pregnancy Outcomes Report Form.  
• Pregnancy outcomes must be collected for the female partners of any males who took study treatment in this study. Consent to report information regarding these pregnancy outcomes should be obtained from the female partner.  
• The pregnancy shall be followed every 3 months during pregnancy till its outcome and 1  month post -
delivery. If there are abnormalities present at delivery, the newbor n will be followed for an appropriate 
period, or up to 3 months, to assess the functional and health status of the child.  
• Pregnancies must be reported to  using the 
reporting details provided in Section  8.3.4 within 24 hours of awareness.  
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( eg, hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease). 
An SAE is defined as, but is not limited to, an event that:  
a) Results in death  
Death is not an AE in itself, but an outcome. The cause of the death is the AE which resulted in death.  
b) Is life -threatening  
Life-threatening means that the subject was at immediate risk of death at the time of the SAE; it does not 
refer to an SAE that hypothetically might have caused death if it had been more severe. .  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 79 c) Requires inpatient hospitalization or prolongation of existing hospitalization  
Hospitalization is defined as at least 1 overnight formal admission into hospital, usually in order to perform 
additional tests, provide treatment which it is not possible to provide at home and/o r due to an unstable 
medical condition which requires specific monitoring of the subject. Pre -planned hospitalizations (known 
already prior to signing the ICF) for pre -existing condition, or a procedure required by the Clinical 
Investigation Plan, without a serious deterioration in health or if the hospitalization is clearly not associated 
with an AE (eg, social hospitalization) will not be considered an SAE, unless any of the above criteria are 
fulfilled over the course of the hospitalization due to unplanned complications. Any Hospitalization due to 
logistic reason will not be considered as SAE” “Social” hospitalization whereby it is administratively impossible to release the subject home is not necessarily an SAE. Complications that occur during hospitalizations are AEs unless they would qualify as an SAE for any of the above criteria. If the complication delays subject release from hospital, then the AE becomes an SAE. Hospitalizations which 
are not performed due to an AE are not regarded as SAEs.  
d) Result s in persistent or significant disability/incapacity  
The term significant disability refers to any condition that impairs physical/physiological well -being to the 
extent that the subject is unable to function normally. Physical disability may include, but is not limited to, permanent disability of locomotion or motility, but also systemic permanent dysfunction including heart 
failure, liver insufficiency or pulmonary fibrosis.
 
e) Is a congenital anomaly/birth defect  
f) Is an important medical event:  
Important m edical events that may not result in death, be life -threatening or require hospitalization may be 
considered as an SAE when, based on appropriate medical judgment, they may jeopardize the subject, or the subject may require medical or surgical intervention  to prevent one of the outcomes listed in this 
definition.
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 80 Recording and Follow- up of AE and/or SAE  
Definition of the Adverse Event Reporting Period  
The AE/ SAE reporting period for safety surveillance begins after subject signs ICF. The safety 
surveillance continues until 20 weeks from last dose of study treatment administration. Any AE/-SAE occurred post 20 weeks from last dose of study treatment administration will be 
reported if it is considered related to study treatment by the Investigator.  
Unexpected Adverse Event  
Any adverse event that is not identified in nature, severity, frequency or outcome in Investigator 
Brochure (IB)  will be considered as unexpected. Most recent version of IB will serve as 
reference safety information for assessment  of expectedness of SAEs.  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all  documentation (eg, 
hospital progress notes, laboratory reports, and diagnostics reports) related to the event.  
• The Investigato r will then record all relevant AE/SAE information in the eCRF. Each event must be 
recorded separately.  
• It is not  acceptable for the Investigator to send photocopies of the subject’s medical records to  
 in lieu of completion of the/AE/SAE eCRF page.  
• There may be instances when copies of medical records for certain cases are requested by  
. In this case, all subject identifiers, with the exception 
of the subject number, will be redacted on the copies of the medical records before submission to 
. 
• The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE.  
Assessment of Intensity  
The Investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs 
and SAEs can be assessed as severe.  
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.  
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 81 Assessment of Causality  
• The Investigator is obligated to assess the relationship between study treatment and each occurrence of 
each AE/SAE. The AE must be characterized as certainly/definitely related, unrelated, unlikely to be related , possibly related, or probably related.  
o “Certainly/definitely related” suggests that a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to drug administration, and which 
cannot be explained by concurrent disease or other drugs or chemicals. The response to 
withdrawal of the drug (de -challenge) should be clinically plausible. The event must be 
definitive pharmacologically or phenomenologically, using a satisfactory re -challenge 
procedure if necessary.  
o “Prob ably related” conveys that there are facts, evidence, and/or arguments to suggest a 
causal relationship, rather than a relationship cannot be ruled out.  
o “Possibly related” suggests that the association of the AE with the study treatment is unknown; however , the AE is not reasonably supported by other conditions.  
o “Unlikely to be related” suggests that only a remote connection exists between the study treatment and the AE. Other conditions, including chronic illness, progression or expression of the disease state or reaction to concomitant therapy, appear to explain the reported AE.  
o “Unrelated” is used if there is not a reasonable possibility that the study treatment caused the AE.  
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well 
as the temporal relationship of the event to study treatment administration will be considered and 
investigated.  
• The Investigator will also consult the IB and/or Product Information, for marketed products, in his/her 
assessment.  
• For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which  an SAE has occurred, and the Investigator has minimal information 
to include in the initial report to . However, it 
is very important that the Investigator always make an assessment of causality for every event before the initial transmission of the SAE data to . 
• The Investigator may change his/her opinion of causality in light of follow -up information and send a 
SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
Action Taken with respect to study treatment  
Action taken is categorized as “none”, “study treatment discontinued permanently”, “study treatment discontinued temporarily and restarted”, or unknown.  
Event Outcome  
Event outcome recorded and categorized as “Fatal”, “Resolved”, “Resolved with sequelae”, “Resolving”, “Not Resolved”, or “Unknown”.  
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 82 Follow -up of AEs and SAEs  
• The Investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by  
 to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or consultation with other healt h care professionals.  
• If a subject dies during participation in the study or during a recognized follow -up period, the 
Investigator will provide  with a copy of any postmortem findings including 
histopathology.  
• New or updated infor mation will be recorded in the originally completed eCRF.  
• The Investigator will submit any updated SAE data to the  
 within 24 hours of receipt of the information.  
Follow -up of unresolved AEs and SAEs  
Any AE/ SAE unresolved at end of study visit will be followed until resolution/ stabilization or as per medical judgment of the Investigator.  
 
Reporting of SAEs 
SAE Reporting to  via Paper Case Report 
Form (CRF)  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit this information to 
the  
• In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.  
• Initial notification via telephone does not replace the need for the Investigator to complete and sign the SAE CRF pages within the designated reporting time frames.  
Safety Reporting to Sponsor  
•  will forward the SAE and Pregnancy report to 
the Sponsor’s safety representatives within 1 business day or 3 calendar days (whichever is earlier) of 
becoming aware of it.  
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 84 APPENDIX 6: EXCLUDED MEDICATIONS/THERAPY  
Excluded medications/therapy is listed below. The concomitant use of an excluded 
medication/therapy with study treatment is not in compliance with the study protocol and must 
be recorded in the eCRF.  
  
   
 
 
  
 
 
  
  
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 85 APPENDIX 7: CONTRACEPTIVE GUIDANCE AND COLLECTION OF  
PREGNANCY  
Definitions : 
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently  sterile (see below).  
Women in the following categories are not considered WOCBP 
6. Premenarchal  
7. Premenopausal female with 1 of the following: 
a) Documented hysterectomy . 
b) Documented bilateral salpingectomy . 
c) Documented bilateral oophorectomy. Note:  Documentation can come from the study center personnel’s: review of the subject ’s 
medical records, medical examination, or medical history interview.  
8. Postmenopausal female: a) A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contracep tion or hormonal replacement therapy (HRT). However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient.  
b) Females on HRT and whose menopausal status is in doubt will be required to use 1 of the non-estrogen hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before study enrollment. 
Contracept ion Guidance  
Male  subjects  
• Male subjects with female  partners of childbearing potential are eligible to participate if they  
agree to 1 of the following during the study and for 6 months after the last dose of study 
treatment :  
o Are abstinent from penile-vaginal intercourse as their usual and preferred lifest yle 
(abstinent on a long- term and persistent basis) and agree to remain abstinent . 
o Agree to use a male condom plus partner use of a contraceptive method with a failure rate of <1% per year when having penile-vaginal intercourse with a woman of 
childbearing  potential who is not currently pregnant. 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 86 • In addition, male subjects must refrain from donating sperm for the duration of the study and 
for 6 months after the last dose of study treatment . 
• Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile-vaginal intercourse or use a male condom during each episode of penile penetration for the  duration of the study and for 6 months after the last dose of the study treatment.  
Female subjects  
Female subjects of childbearing pot ential are eligible to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described in the table below . 
Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Depen dent a  
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulationb  
• Oral.  
• Intravaginal.  
• Transdermal.  
Progestogen only hormonal contraception associated with inhibition of ovulation  
• Oral.  
• Injectable.  
Highly Effective Methods That Are User Independent a  
Implantable progestogen only hormonal contraception associated with inhibition of ovulationb 
• Intrauterine device (IUD). 
• Intraut erine hormone -releasing system (IUS).  
Bilateral tubal occlusion.  
Vasectomized partner  
A vasectomized partner is a highly effective birth control method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has be en confirmed. If not, an additional highly effective method 
of contraception should be used.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period  of risk associated with the study treatment. The reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.   
NOTES:  
a Typical use failure rates may differ from th ose when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for subjects participating in clinical studies.  
b Hormonal contraception may be susceptible to interaction with the study treatment, which may reduce the efficacy 
of the contraceptive method. In this case, 2 highly effective methods of contraception should be utilized during 
the treatment period and for at least 6 months , after the last dose of study treatment.  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 88 Investigator is not obligated to actively seek this information in former subject s, he or she 
may learn of an SAE through spontaneous reporting.  
• Any female subject who becomes pregnant while participating in the study will discontinue 
study treatment or be withdrawn from the study. 
• The pregnancy shall be followed every 3 months during pregnancy till its outcome and one 
month post-delivery. If there are abnormalities present at delivery, the newborn will be 
followed for an appropriate period, or up to 3 months, to assess the functional and health status of the child. 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 89    
 
 
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 90   
 
   
 
   
 
 
    
  
 
 
 
   
 
 
 
   
 
 
 
    
 
 
 
 
 
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 91   
   
 
   
 
 
   
  
  
 
 
   
 
 
 
   
 
 
 
    
 
 
 
 
 
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 95   
 
   
 
   
 
   
 
 
 
 
 
 
   
 
 
   
 
 
    
 
 
 
 
 
 
    
 
    
 
    
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 96   
   
   
    
 
 
 
   
 
 
   
 
 
    
 
 
 
 
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 97   
 
 
 
 
 
 
  
 
 
 
   
 
 
 
 
   
  
  
  
 
  
   
  
 
 
 
 
  
  
  
 
  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 98   

CONFIDENTIAL  Protocol TILD -18-20- 
  
 99   

CONFIDENTIAL  Protocol TILD -18-20- 
  
 100 APPENDIX 19: COLUMBIA- SUICIDE SEVERITY RATING SCALE  
1) C-SSRS Screening  
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 101  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 103 2) C-SSRS Baseline  

CONFIDENTIAL  Protocol TILD -18-20- 
  
 106 3) C-SSRS Since Last Visit 
 

CONFIDENTIAL  Protocol TILD -18-20- 
  
 107  

CONFIDENTIAL  Protocol TILD -18-20- 
  
   

CONFIDENTIAL  Protocol TILD -18-20- 
  
 109   
 
 
 
  
     
 
 
 
 
 
 
 
 
                   
                          
                    
        
 
    
     
 
 
 
